Streetbeat News

Products Services

DTIL

LLY

Precision BioSciences, Inc. has amended and restated its development and license agreement with Prevail Therapeutics Inc., a subsidiary of Eli Lilly and Company, to collaborate on developing potential in vivo therapies for genetic disorders.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:07 pm

LI

NIO

XPEV

Chinese EV manufacturer Li Auto has outperformed traditional automakers in China's EV market, delivering nearly 87,000 cars in the last quarter, a threefold increase from the previous year. Meanwhile, deliveries for competitors Xpeng and Nio fell over the same period. Traditional automakers like Guangzhou Automobile and Geely Automobile are also adapting their strategies to the growing EV market. The latter's premium Zeekr brand has seen rapid growth, with deliveries increasing 147% YoY in June.

Portfolio Pulse from Benzinga Newsbot

July 06, 2023 | 12:07 pm

RDHL

Phil Inc. has partnered with RedHill Biopharma (NASDAQ:RDHL) to make RedHill's medication Talicia® available via the PhilRx Patient Access Platform. The platform simplifies the prescription process, including insurance coverage and reimbursement. The partnership aims to increase patient access to Talicia®, a treatment for Helicobacter pylori infection.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:05 pm

HZNP

Horizon Therapeutics (NASDAQ:HZNP) has published long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA injection with methotrexate in ACR Open Rheumatology. The 12-month data reinforces key findings shown at Month 6, including the durability of urate-lowering response, reduced infusion reactions, and reduced immunogenicity of pegloticase when co-administered with methotrexate. The patient response rate remained nearly 30 percentage points higher with methotrexate co-therapy during Month 12.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:04 pm

AKTX

Akari Therapeutics, Plc (NASDAQ:AKTX) has received a positive opinion from the European Medicines Agency (EMA) on its application for orphan drug designation for nomacopan, a treatment in hematopoietic stem cell transplantation. The company is currently conducting a Phase 3 clinical trial of nomacopan in pediatric HSCT-TMA.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:03 pm

CLDX

Celldex Therapeutics has announced that the first patient has been dosed in a Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis. This marks a significant step in the development of the drug.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:03 pm

AAPL

SSNLF

Samsung Electronics Co, Ltd's Q2 profit is expected to plunge 96% YoY, the lowest in over 14 years, due to an oversupply of chips. The company's chip division likely reported quarterly losses of around 3-4 trillion won. Samsung is trying to grow its share of chip demand from the AI field. Its mobile business likely reported an operating profit of around 3.3 trillion won. Samsung plans to launch its latest foldable smartphones in July, earlier than usual, to dominate the premium phone market before Apple releases its next iPhone.

Portfolio Pulse from Anusuya Lahiri

July 06, 2023 | 12:02 pm

CRIS

The FDA has lifted the partial clinical hold on Curis' TakeAim Leukemia Study, with the recommended phase 2 dose (RP2D) established at 300 mg twice daily. This could potentially accelerate the development and approval process for Curis' leukemia treatment.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:02 pm

PXMD

PaxMedica, Inc. (NASDAQ:PXMD) has signed an exclusive pharmacy distribution agreement with Vox Nova LLC for its lead pipeline asset, PAX-101. PaxMedica is a biopharmaceutical company focused on developing novel anti-purinergic drug therapies for Autism Spectrum Disorder (ASD) and other neurological conditions.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:01 pm

ASLN

ASLAN Pharmaceuticals announced that the eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints with statistical significance.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 11:59 am